Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 161

Similar articles for PubMed (Select 21960219)

1.

Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.

Duncan JS, Haystead TA, Litchfield DW.

Methods Mol Biol. 2012;795:119-34. doi: 10.1007/978-1-61779-337-0_8.

PMID:
21960219
2.

Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.

Gyenis L, Turowec JP, Bretner M, Litchfield DW.

Biochim Biophys Acta. 2013 Jul;1834(7):1352-8. doi: 10.1016/j.bbapap.2013.02.006. Epub 2013 Feb 14. Review.

PMID:
23416530
3.

Sensitizing plant protein kinases to specific inhibition by ATP-competitive molecules.

Salomon D, Zhang C, Shokat KM, Sessa G.

Methods Mol Biol. 2011;779:185-97. doi: 10.1007/978-1-61779-264-9_10.

PMID:
21837567
4.

A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.

Bogoyevitch MA, Fairlie DP.

Drug Discov Today. 2007 Aug;12(15-16):622-33. Epub 2007 Aug 2. Review.

PMID:
17706543
6.

Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.

Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Gerlach M, Missio A, Cotten M, Müller S, Daub H.

Mol Cell Proteomics. 2004 Dec;3(12):1181-93. Epub 2004 Oct 8.

7.

Large-scale proteomics analysis of the human kinome.

Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Kéri G, Mann M, Daub H.

Mol Cell Proteomics. 2009 Jul;8(7):1751-64. doi: 10.1074/mcp.M800588-MCP200. Epub 2009 Apr 15.

8.

Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.

Laufer SA, Domeyer DM, Scior TR, Albrecht W, Hauser DR.

J Med Chem. 2005 Feb 10;48(3):710-22.

PMID:
15689155
9.

Kinase inhibitor profiling using chemoproteomics.

Schirle M, Petrella EC, Brittain SM, Schwalb D, Harrington E, Cornella-Taracido I, Tallarico JA.

Methods Mol Biol. 2012;795:161-77. doi: 10.1007/978-1-61779-337-0_11.

PMID:
21960222
10.

Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2.

Gyenis L, Kuś A, Bretner M, Litchfield DW.

J Proteomics. 2013 Apr 9;81:70-9. doi: 10.1016/j.jprot.2012.09.017. Epub 2012 Sep 25.

PMID:
23017496
11.

Affinity purification of proteins binding to kinase inhibitors immobilized on self-assembling monolayers.

Bantscheff M, Hobson S, Kuster B.

Methods Mol Biol. 2012;795:149-60. doi: 10.1007/978-1-61779-337-0_10.

PMID:
21960221
12.

Detection of allosteric kinase inhibitors by displacement of active site probes.

Lebakken CS, Reichling LJ, Ellefson JM, Riddle SM.

J Biomol Screen. 2012 Jul;17(6):813-21. doi: 10.1177/1087057112439889. Epub 2012 Mar 26.

PMID:
22453235
13.

Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.

Kirkland LO, McInnes C.

Biochem Pharmacol. 2009 May 15;77(10):1561-71. doi: 10.1016/j.bcp.2008.12.022. Epub 2009 Jan 10.

PMID:
19167366
14.

Recent advances in designing substrate-competitive protein kinase inhibitors.

Han KC, Kim SY, Yang EG.

Curr Pharm Des. 2012;18(20):2875-82. Review.

PMID:
22571656
15.

Off-target decoding of a multitarget kinase inhibitor by chemical proteomics.

Missner E, Bahr I, Badock V, Lücking U, Siemeister G, Donner P.

Chembiochem. 2009 May 4;10(7):1163-74. doi: 10.1002/cbic.200800796.

PMID:
19350611
16.

Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.

Comess KM, Sun C, Abad-Zapatero C, Goedken ER, Gum RJ, Borhani DW, Argiriadi M, Groebe DR, Jia Y, Clampit JE, Haasch DL, Smith HT, Wang S, Song D, Coen ML, Cloutier TE, Tang H, Cheng X, Quinn C, Liu B, Xin Z, Liu G, Fry EH, Stoll V, Ng TI, Banach D, Marcotte D, Burns DJ, Calderwood DJ, Hajduk PJ.

ACS Chem Biol. 2011 Mar 18;6(3):234-44. doi: 10.1021/cb1002619. Epub 2011 Jan 20.

PMID:
21090814
17.

Binding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurements.

Defranchi E, Schalon C, Messa M, Onofri F, Benfenati F, Rognan D.

PLoS One. 2010 Aug 16;5(8):e12214. doi: 10.1371/journal.pone.0012214. Erratum in: PLoS One. 2010;5(10). doi: 10.1371/annotation/95078306-dc3b-4441-b2b1-dd986b734570. De Franchi, Enrico [corrected to Defranchi, Enrico].

18.

Structural aspects of protein kinase control-role of conformational flexibility.

Engh RA, Bossemeyer D.

Pharmacol Ther. 2002 Feb-Mar;93(2-3):99-111. Review.

PMID:
12191603
19.

Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.

Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.

J Pharm Belg. 1997 Mar-Apr;52(2):88-96. Review.

PMID:
9193132
20.

Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors.

Peters EC, Gray NS.

ACS Chem Biol. 2007 Oct 19;2(10):661-4.

PMID:
18041816
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk